The results indicated that SSPN, CD52, VPREB3, and CCDC82 were independent prognostic biomarkers, and the four-gene or five-gene signature could be developed as a promising prognostic biomarker panel for human DLBCL (Figure 4C). This evidence concerns the gene CCDC82 and diffuse large B-cell lymphoma.